Sign In
Buy ALEC
$1.51
-0.110 (-6.79%)
At Close: Jul 31, 2026
Alector shares plunge after dementia drug fails to slow disease progression
06:41pm, Tuesday, 21'st Oct 2025
Alector said on Tuesday its experimental drug failed to slow the progression of a rare form of dementia in a late-stage trial, prompting the company to end the study and cut nearly half its workforce.
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progre
Alector, Inc. (NASDAQ:ALEC) Receives $4.17 Average PT from Analysts
01:30am, Monday, 20'th Oct 2025
Shares of Alector, Inc. (NASDAQ: ALEC - Get Free Report) have been assigned an average recommendation of "Hold" from the eight research firms that are covering the stock, MarketBeat reports. Three equ
Alector, Inc. - Special Call
09:03pm, Monday, 22'nd Sep 2025
Alector, Inc. - Special Call Company Participants Katie Hogan - Senior Director of Corporate Communication & Investor Relations Sara Kenkare-Mitra - President and Head of Research & Development Arnon
Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs
08:00am, Tuesday, 16'th Sep 2025
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating
Alector, Inc. (ALEC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
04:45pm, Monday, 08'th Sep 2025
Alector, Inc. (NASDAQ:ALEC ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 10:00 AM EDT Company Participants Arnon Rosenthal - Co-Founder, CEO & Director Conference Call Pa
Alector to Participate in Upcoming Healthcare Conferences
08:00am, Thursday, 28'th Aug 2025
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating
After Golden Cross, Alector (ALEC)'s Technical Outlook is Bright
10:55am, Friday, 22'nd Aug 2025
After reaching an important support level, Alector, Inc. (ALEC) could be a good stock pick from a technical perspective. ALEC recently experienced a "golden cross" event, which saw its 50-day simple m
Alector, Inc. (ALEC) Q2 2025 Earnings Call Transcript
02:35am, Saturday, 09'th Aug 2025
Alector, Inc. (NASDAQ:ALEC ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Arnon Rosenthal - Co-Founder, CEO & Director Giacomo Salvadore - Chief Medical Officer Kati
Alector (ALEC) Q2 Revenue Falls 48%
07:52pm, Thursday, 07'th Aug 2025
Alector (ALEC) Q2 Revenue Falls 48%
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates
07:16pm, Thursday, 07'th Aug 2025
Alector (ALEC) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.4 per share a year ago.
Alector Reports Second Quarter 2025 Financial Results and Provides Business Update
04:05pm, Thursday, 07'th Aug 2025
On track to report topline data by mid-Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia with no approved treatments Ongoing Phase 2
Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call
04:05pm, Thursday, 31'st Jul 2025
Call Scheduled for Thursday, August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Thursday, August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PT
Alector Provides Executive Leadership Update
04:05pm, Friday, 13'th Jun 2025
-- Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., effective June 20, 2025 -- SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Alector, I
Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
08:00am, Tuesday, 03'rd Jun 2025
SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating
